Evolus offers a highly asymmetric modeled upside, but margin compression, insider selling, a failed momentum gate, and an extreme put/call ratio all flag elevated risk.
Thesis pillars
- Value Trap Margin Compression Insider Selling—
- Extreme Asymmetric Upside—
- Momentum Gate Failure—
- +1 more pillar — see the Why tab for full reasoning
Evolus, Inc. Common Stock (EOLS) Stock Analysis
Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $8.16: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Evolus, Inc. is a global performance beauty company selling Jeuveau®, an injectable botulinum toxin type A for frown lines, and Evolysse™, a line of injectable hyaluronic acid gel fillers, to licensed aesthetic practitioners in the cash-pay aesthetic market. The company... Read more
Sell if holding. Engine safety override at $8.16: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.2/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-08-17Recent Developments — Evolus, Inc. Common Stock
Latest news
- NEWS Evolus Enters Into Exclusive Licensing And Distribution Agreement With IBSA To Develop And Commercialize Profhilo In US — benzinga Jul 8, 2026 positive
Generated 2026-08-01T10:18:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierDaewoong (Jeuveau manufacturer)10-K Item 1: 'Daewoong Pharmaceuticals Co. Ltd. ("Daewoong") manufactures and supplies Jeuveau® to us.'
- HIGHSupplierSymatese (Evolysse manufacturer)10-K Item 1: 'Symatese Aesthetics S.A.S. ("Symatese") manufactures and supplies Evolysse™ to us.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -10.8%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.16: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $7.59. Score 6.2/10, moderate confidence.
Take-profit target: $12.76 (+56.4% upside). Prior stop was $7.59. Stop-loss: $7.59.
Concentration risk — Supplier: Daewoong (Jeuveau manufacturer); Concentration risk — Supplier: Symatese (Evolysse manufacturer); Quality below floor (3.6 < 4.0).
Evolus, Inc. Common Stock trades at a P/E of N/A (forward 31.6). TrendMatrix value score: 8.2/10. Verdict: Sell.
13 analysts cover EOLS with a consensus score of 4.2/5. Average price target: $15.
What does Evolus, Inc. Common Stock do?Evolus, Inc. is a global performance beauty company selling Jeuveau®, an injectable botulinum toxin type A for frown...
Evolus, Inc. is a global performance beauty company selling Jeuveau®, an injectable botulinum toxin type A for frown lines, and Evolysse™, a line of injectable hyaluronic acid gel fillers, to licensed aesthetic practitioners in the cash-pay aesthetic market. The company generates revenue from direct-to-practitioner sales in the U.S., Canada, Europe, and Australia, with Jeuveau® manufactured exclusively by Daewoong Pharmaceutical in South Korea and Evolysse™ manufactured exclusively by Symatese in France.